---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009225"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:08:49.420964+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics doses first patient in Phase 1 trial of oral WEE1 inhibitor APR-1051

## Summary
- First patient dosed in ACESOT-1051 Phase 1 trial of oral WEE1 inhibitor APR-1051 as monotherapy in advanced solid tumors.
- APR-1051 is a potent, highly selective WEE1 inhibitor designed to limit off-target PLK inhibition and improve PK profile.
- Trial targets tumors with CCNE1/2 amplification, FBXW7/PPP2R1A mutations, KRAS-G12/TP53 co-mutated CRC, or uterine serous carcinoma.
- Dose escalation (up to 39 patients) and dose optimization (up to 40 patients) to determine RP2D; first site at NEXT Oncology (San Antonio).
- Company expects clinical update by year-end 2024 and preliminary efficacy data in 2025.

## SEC filing metadata
- accession: 0001558370-24-009225
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/0001558370-24-009225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024009225/apre-20240617x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009225
- JSON: https://secwatch.observer/filing/0001558370-24-009225.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009225.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.